亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Medication Formulation Preference of Mild and Moderate Ulcerative Colitis Patients: a European Survey

医学 溃疡性结肠炎 氨基水杨酸 药丸 炎症性肠病 内科学 偏爱 疾病 家庭医学 物理疗法 护理部 经济 微观经济学
作者
Xavier Hébuterne,Stephan R. Vavricka,Helen C. Thorne,L Mackenzie-Smith,R Laoun,Johan Burisch
出处
期刊:Inflammatory intestinal diseases [S. Karger AG]
卷期号:8 (1): 41-50
标识
DOI:10.1159/000530139
摘要

Introduction: Patient adherence is a major challenge for the successful management of any chronic disease, and ulcerative colitis (UC) is no exception. Patient adherence is closely related to patient preference of medication and formulation used. Aim: The aim of this study was to investigate patient and physician perspectives around UC treatment preference. Methods: This study was conducted in France, Germany, Spain, and the UK. Physicians and UK inflammatory bowel disease (IBD) nurses answered an online questionnaire. In addition, adult mild-to-moderate UC patients, treated with oral mesalazine, were invited to answer a 30-min online survey which included a conjoint exercise. Results: 400 patients, 160 physicians, and 20 IBD nurses participated in the survey. 68% of patients were taking tablets and 32% granules. Physicians stated that from their perspective patients are more adherent to tablets than granules (76% vs. 24%), patients tended to have better relief of symptoms with tablets (69% vs. 31%), and patients found tablets to be the most convenient formulation (61% vs. 39%). From the patients’ perspective, when questioned which formulation they prefer, 58% answered tablets, 37% granules, and 5% none of these. When patients were asked about some negative attributes of tablets, the highest agreement was for “I would like to take fewer each day” (6.1/10) and “I wish I could take fewer at a time” (5.4/10). Conclusions: The majority of UC patients in this survey prefer the tablet formulation. A high strength tablet overcoming the high pill burden could be a good solution to address patient expectations.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
江三村完成签到 ,获得积分10
35秒前
1分钟前
245完成签到,获得积分10
1分钟前
245发布了新的文献求助10
1分钟前
传奇完成签到 ,获得积分10
1分钟前
领导范儿应助微笑紫真采纳,获得10
2分钟前
今后应助善良山灵采纳,获得10
3分钟前
刻苦的芜完成签到 ,获得积分10
3分钟前
yishan完成签到,获得积分10
4分钟前
陈无敌完成签到 ,获得积分10
4分钟前
4分钟前
善良山灵发布了新的文献求助10
4分钟前
科研小白鼠完成签到 ,获得积分10
4分钟前
善良山灵完成签到,获得积分10
5分钟前
woxinyouyou完成签到,获得积分0
8分钟前
1461完成签到 ,获得积分10
8分钟前
13分钟前
微笑紫真发布了新的文献求助10
13分钟前
14分钟前
温哒哒发布了新的文献求助10
14分钟前
桐桐应助温哒哒采纳,获得10
14分钟前
微笑紫真完成签到,获得积分10
14分钟前
CipherSage应助微笑紫真采纳,获得10
14分钟前
nsk810431231完成签到 ,获得积分10
14分钟前
15分钟前
pentayouth发布了新的文献求助10
15分钟前
15分钟前
小巧的斌发布了新的文献求助10
15分钟前
领导范儿应助无语的无语采纳,获得10
16分钟前
qqJing完成签到,获得积分10
17分钟前
18分钟前
滚珠子发布了新的文献求助10
18分钟前
滚珠子完成签到,获得积分20
19分钟前
aniu完成签到 ,获得积分10
21分钟前
今后应助科研通管家采纳,获得10
22分钟前
23分钟前
颜沛文完成签到,获得积分10
24分钟前
24分钟前
爆米花应助jarrykim采纳,获得10
24分钟前
shinysparrow应助yishan采纳,获得10
26分钟前
高分求助中
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 1000
巫和雄 -《毛泽东选集》英译研究 (2013) 800
Yuwu Song, Biographical Dictionary of the People's Republic of China 700
[Lambert-Eaton syndrome without calcium channel autoantibodies] 520
The three stars each: the Astrolabes and related texts 500
Revolutions 400
Diffusion in Solids: Key Topics in Materials Science and Engineering 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2451013
求助须知:如何正确求助?哪些是违规求助? 2124465
关于积分的说明 5405784
捐赠科研通 1853254
什么是DOI,文献DOI怎么找? 921688
版权声明 562263
科研通“疑难数据库(出版商)”最低求助积分说明 493029